UBE2N and prostate carcinoma: Immunofluorescence showed that shUBE2N-xenograft presented decreased PCNA-positive cells than shNC-xenograft (Fig. 3D and E), suggesting that knockdown of UBE2N suppresses prostate cancer tumor growth in vivo.